Huiping Xu

Huiping Xu

Auto-generated profile, based on publicly available information

Huiping Xu

Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, United States

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
MWMohammed Rayyan Waseem
Mohammed Rayyan Waseem
ASAndrea Shin
Andrea Shin
RSRobert Siwiec
Robert Siwiec
TJToyia James-Stevenson
Toyia James-Stevenson
MBMatthew Bohm
Matthew Bohm
HXHuiping Xu
Huiping Xu
INTRODUCTION: Short-chain fatty acids (SCFAs) correlate with colonic transit time (CTT) and may influence irritable bowel syndrome (IBS) pathophysiology. However, the clinical significance of fecal SCFAs, relationships between SCFAs and other metabolites (bile acids [BAs]), and real-time diet effects on SCFAs in IBS are uncertain. The aim was to evaluate fecal SCFA associations with IBS phenotype and mechanisms and explore effects of real-time diet. METHODS: We conducted a prospective observational study of fecal SCFA, BAs, and CTT in healthy controls (HCs) and participants with IBS. We compared study end points across groups, analyzed relationships between end points, and evaluated the discriminative ability of SCFAs. Diet effects were explored in participants with dietary data. RESULTS: Among 21 HCs and 43 participants with IBS, fecal SCFAs (total, individual) were inversely correlated with overall (all P < 0.01) and segmental (all P < 0.05) CTT; similar associations were observed within HC and IBS groups. The acetate-to-butyrate ratio correlated with slower overall and left CTT in all and in HCs (both P < 0.01). SCFAs (total, acetate) correlated with BAs (total, % primary) in all participants and in those with IBS with diarrhea. Logistic regression analyses demonstrated associations of acetate with slower transit (odds ratio = 0.988, P = 0.002) and BA diarrhea (BAD; odds ratio = 1.014, P = 0.001). Acetate accurately predicted delayed CTT (area under the receiving operating characteristic curve = 0.84) and BAD (area under the receiver operating characteristic curve = 0.79). Adjusting for diet strengthened correlations of total SCFAs with overall CTT (R = [−0.46], P = 0.04) and SCFAs with transverse CTT (all P < 0.05). DISCUSSION: Fecal SCFAs correlate with CTT and fecal BAs and reliably exclude delayed CTT and BAD. Accounting for diet strengthens SCFA associations with transit.

27 February 2021 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
BRBradley Ray
Bradley Ray
DWDennis Watson
Dennis Watson
HXHuiping Xu
Huiping Xu
MSMichelle P. Salyers
Michelle P. Salyers
GVGrant Victor
Grant Victor
NBNa Bo
Na Bo

1 January 2020 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
DWDennis Watson
Dennis Watson
KBKrista Brucker
Krista Brucker
AMAlan McGuire
Alan McGuire
NSNyssa Snow-Hill
Nyssa Snow-Hill
HXHuiping Xu
Huiping Xu
JKJeffrey A. Kline
Jeffrey A. Kline

9 April 2021 in FEMS Microbiology Letters
Verified
Journal Article
Open access
PDF file
CLCraig Lammert
Craig Lammert
ASAndrea Shin
Andrea Shin
HXHuiping Xu
Huiping Xu
CHChristopher Hemmerich
Christopher Hemmerich
TOThomas OConnell
Thomas OConnell
NCNaga Chalasani
Naga Chalasani
The gut microbiota and metabolome could play a role in primary biliary cholangitis (PBC) progression. We aimed to assess fecal microbiota and fecal short-chain fatty acids (SCFAs) in PBC according to fibrosis. In a cross-sectional study of 23 PBC patients, fecal microbiota and SCFAs were determined using 16S rRNA sequencing and nuclear magnetic resonance spectroscopy, respectively. Fecal acetate and SCFAs were higher in advanced fibrosis. Advanced fibrosis microbiota exhibited decreased alpha diversity, increased Weisella and a distinct community composition. SCFAs correlated with individual taxa in non-advanced fibrosis. Fecal microbiota and SCFAs correspond to fibrosis in PBC.

12 November 2024 in American Journal of Gastroenterology
Verified
Journal Article
Open access
DKDina Kao
Dina Kao
KWKaren Wong
Karen Wong
HJHumberto Jijon
Humberto Jijon
PMPaul Moayyedi
Paul Moayyedi
RFRose Franz
Rose Franz
KMKAREN MADSEN
KAREN MADSEN
INTRODUCTION: Fecal microbiota transplantation (FMT) has shown promise at inducing remission in ulcerative colitis. This study is the first of its kind to evaluate the efficacy and safety of FMT at inducing remission in Crohn's disease (CD). METHODS: This double-blind, placebo-controlled trial was conducted in 3 Canadian academic centers; randomized patients with mild-to-moderate CD received FMT or placebo. The first treatment was administered by colonoscopy followed by weekly oral capsules for 7 weeks. Primary end point was clinical and endoscopic remission at week 8. Secondary outcomes included clinical and endoscopic response, adverse events, and health-related quality of life using generic and disease-specific instruments. RESULTS: From July 2017 to June 2021, 21 and 13 patients were randomized to FMT and placebo groups, respectively. The trial terminated early due to futility. At week 8, 0% (0/15) of patients in the FMT group versus 8.3% (1/11) in the placebo group reached the primary end point of combined clinical and endoscopic remission as per protocol analysis. There were no differences between the groups in clinical or endoscopic responses. One patient in each group had worsening of CD. Although both groups experienced statistically significant improvements in health-related quality of life, only the FMT group had a significant decrease in activity impairment. Although there were no significant changes in microbial diversity or composition, patients who achieved clinical response became more similar to their donors in stool microbial composition. DISCUSSION: FMT was not effective at inducing clinical and endoscopic remission in CD using the FMT regimen in this study. Future studies may use other strategies to enhance treatment response, including longer intervention, antibiotic pretreatment, optimized donor-recipient pairing, and concomitant anti-inflammatory diet, and biologic or small molecule therapies.

9 February 2016 in BMC Emergency Medicine
Verified
Journal Article
Open access
PDF file
JWJianmin Wu
Jianmin Wu
SGShaun J. Grannis
Shaun J. Grannis
HXHuiping Xu
Huiping Xu
JFJohn T. Finnell
John T. Finnell
Accurately predicting future frequent emergency department (ED) utilization can support a case management approach and ultimately reduce health care costs. This study assesses the feasibility of using routinely collected registration data to predict future frequent ED visits. Using routinely collected registration data in the state of Indiana, U.S.A., from 2008, we developed multivariable logistic regression models to predict frequent ED visits in the subsequent two years. We assessed the model’s accuracy using Receiver Operating Characteristic (ROC) curves, sensitivity, and positive predictive value (PPV). Strong predictors of frequent ED visits included age between 25 and 44 years, female gender, close proximity to the ED (less than 5 miles traveling distance), total visits in the baseline year, and respiratory and dental chief complaint syndromes. The area under ROC curve (AUC) ranged from 0.83 to 0.92 for models predicting patients with 8 or more visits to 16 or more visits in the subsequent two years, suggesting acceptable discrimination. With 25 % sensitivity, the model predicting frequent ED use as defined as 16 or more visits in 2009 and 2010 had a PPV of 59.5 % and specificity of 99.9 %. The “adjusted” PPV of this model, which includes patients having 8 or more visits, is 81.9 %. We demonstrate a strong association between predictor variables present in registration data and frequent ED use. The algorithm’s performance characteristics suggest that it is technically feasible to use routinely collected registration data to predict future frequent ED use.